USRE42327E1 - Medicinal compositions improving brain function and method for improving brain function - Google Patents

Medicinal compositions improving brain function and method for improving brain function Download PDF

Info

Publication number
USRE42327E1
USRE42327E1 US12/683,813 US68381304A USRE42327E US RE42327 E1 USRE42327 E1 US RE42327E1 US 68381304 A US68381304 A US 68381304A US RE42327 E USRE42327 E US RE42327E
Authority
US
United States
Prior art keywords
group
ingredient
compound
pharmaceutical composition
ethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime, expires
Application number
US12/683,813
Inventor
Yasushi Nakada
Masaya Nakagawa
Satoshi Ono
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toyama Chemical Co Ltd
Original Assignee
Toyama Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyama Chemical Co Ltd filed Critical Toyama Chemical Co Ltd
Application granted granted Critical
Publication of USRE42327E1 publication Critical patent/USRE42327E1/en
Adjusted expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • This invention relates to a pharmaceutical composition for improving the cerebral function which contains an alkyl ether derivative and a compound having acetylcholine esterase inhibiting activity, and to a method using an alkyl ether derivative in combination with a compound having acetylcholine esterase inhibiting activity for the purpose of. improving the cerebral function.
  • drugs for symptomatic treatment of this memory impairment for example, compounds having an acetylcholine esterase inhibiting activity such as Tacrine, Donepezil, and the like are used.
  • the anti-hypoxic activity is used for evaluating the neuroprotective activity in-vitro, and it is reported that, in the in-vivo experiments, too, compounds having a neuroprotective activity show the same effect as above [Ann. N. Y. Acad. Sci., Vol. 890, Pages 406-420, 1999]. Further, it has been reported that the anti-hypoxic activity is shown by compounds activating the in-brain acetylcholine neurons and by Tacrine (1,2,3,4-tetrahydro-9-acridinamine hydrochloride) showing an acetylcholine esterase inhibiting activity [Jpn. J. Pharmacol., Vol. 62, Pages 81-86, 1993].
  • a work for studying the in-vivo anti-hypoxic activity can be regarded as a method for evaluating the compounds having one of the neuroprotective effect and the in-brain acetylcholine neurons activating effect or both of these effects.
  • the 1,2-ethanediol derivatives or salts thereof described in JP 3-232830A and JP 4-95070A are compounds useful as a cerebral function-improving agent, and particularly (R)-1- ⁇ benzo[b]thiophen-5-yl ⁇ -2-[2-(N,N-diethylamino ⁇ ethoxy]ethanol hydrochloride (hereinafter, referred to as T-588) is a preferable compound. It has been reported that T-588 has an anti-hypoxic activity and an anti-amnestic activity, and promotes the release of in-brain acetylcholine (SOCIETY FOR NEUROSCIENCE, Abstracts, Vol. 21, Page 947, 1995).
  • T-588 exhibits a protecting effect on the neuronal death caused by amyloid-beta-protein (SOCIETY FOR NEUROSCIENCE, Abstracts, Vol. 24, Part 1, Page 228, 1998) and that T-588 exhibits an increasing effect on the action of nerve growth factor (WO96/12717).
  • SOCIETY FOR NEUROSCIENCE NEUROSCIENCE, Abstracts, Vol. 24, Part 1, Page 228, 1998)
  • T-588 exhibits an increasing effect on the action of nerve growth factor (WO96/12717).
  • WO96/12717 nerve growth factor
  • acetylcholine esterase inhibiting drugs such as Tacrine, Donepezil, Galanthamine, and the like are commercially available as cerebral function-improving drugs including Alzheimer's disease-curing drug, these drugs have problems in the point of side-reactions because some of them have a hepatic toxicity and some others have a side reaction accompanied by activation of acetylcholine neurons other than central nervous system.
  • acetylcholine esterase inhibiting drugs for example, a combination of a brain circulation metabolism improver such as Idebenone and an acetylcholine esterase inhibitor (JP 10-259126A) or a combination of a compound having a nerve growth factor-like activity (SR57746A) and an acetylcholine esterase inhibitor (WO99/25363), etc. are being attempted.
  • a brain circulation metabolism improver such as Idebenone and an acetylcholine esterase inhibitor
  • SR57746A nerve growth factor-like activity
  • WO99/25363 acetylcholine esterase inhibitor
  • R 1 represents a substituted or unsubstituted heterocyclic group
  • R 2 represents a hydrogen atom or a hydroxyl group
  • R 3 and R 4 which may be the same or different, each represents a substituted or unsubstituted alkyl, or R 3 and R 4 , taken together with the nitrogen atom to which they are linked, form a substituted or unsubstituted cyclic amino group
  • m represents an integer of 1 to 5
  • n represents an integer of 1 to 6; or a salt thereof, including T-588.
  • Halogen atom means a fluorine atom, a chlorine atom, a bromine atom or an iodine atom
  • alkyl group means a straight chain or branched chain C 1-12 alkyl group such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, heptyl, octyl and the like
  • lower alkyl group means a straight chain or branched chain C 1-6 alkyl group such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl and the like
  • alkoxy group means a straight or branched chain C 1-12 alkyloxy group such as methoxy, ethoxy, propoxy, isoprop
  • the heterocyclic group of R 1 may be substituted with at least one residue selected from halogen atom, optionally substituted amino, lower alkyl, aryl, ar-lower alkyl, lower alkoxy, ar-lower alkoxy, aryloxy, carbamoyloxy, lower alkylthio, lower alkenyl, lower alkenyloxy, ar-lower alkylthio, ar-lower alkylsulfonyl, arylsulfonyl, lower alkylsulfonylamino, arylsulfonylamino groups, or optionally protected amino group, optionally protected hydroxyl group, nitro group, heterocyclic group, oxo group, lower alkylenedioxy group and the like.
  • halogen atom optionally substituted amino, lower alkyl, aryl, ar-lower alkyl, lower alkoxy, ar-lower alkoxy, aryloxy, carbamoyloxy, lower alkyl
  • the amino groups of R 3 and R 4 and the cyclic amino group which R 3 and R 4 form in conjunction with the nitrogen atom to which R 3 and R 4 are linked may be substituted with at least one group selected from halogen atom, optionally substituted amino group, lower alkyl group, aryl group, ar-lower alkyl group, ar-lower alkenyl group, aroyl group, ar-lower alkenoyl group, heterocyclic group and the like.
  • R 1 , R 3 , R 4 and the cyclic amino group which R 3 and R 4 form in conjunction with the nitrogen atom to which R 3 and R 4 and linked may further be substituted with at least one group selected from halogen atom, optionally protected hydroxyl group, optionally protected carboxyl group, optionally protected amino group, lower alkyl group, lower alkoxy group, lower acyl group, cycloalkyl group, ar-lower alkyl group and the like.
  • the protecting group for carboxyl group includes all the residues which can conventionally be used as a protecting group for carboxyl group, of which examples include lower alkyl groups such as methyl, ethyl, propyl, isopropyl, 1,1-dimethylpropyl, butyl, tert-butyl and the like; aryl groups such as phenyl, naphthyl and the like; ar-lower alkyl groups such as benzyl, diphenylmethyl, trityl, p-nitrobenzyl, p-methoxybenzyl, bis(p-methoxyphenyl)methyl and the like; acyl-lower alkyl groups such as acetylmethyl, benzoylmethyl, p-nitrobenzoylmethyl, p-bromobenzoylmethyl, p-methanesulfonylbenzoylmethyl and the like; oxygen-containing heterocyclic groups such as 2-tetrahydropyranyl, 2-
  • the protecting group for hydroxyl group include all the residues which can conventionally be used for protection of hydroxyl group, of which examples include acyl groups such as benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl, methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, 1,1-dimethylpropoxycarbonyl, isopropoxycarbonyl, isobutyloxycarbonyl, diphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2,2,2-tribromoethoxycarbonyl, 2-(trimethylsilyl)-ethoxycarbonyl, 2-(phenylsulfonyl)ethoxycarbonyl, 2-(triphenylphosphonio)ethoxycarbonyl, 2-furfuryloxycarbonyl, 1-a
  • the protecting group for amino group include all the residues which can conventionally be used as a protecting group for amino groups, of which examples include acyl groups such as trichloroethoxycarbonyl, tribromoethoxycarbonyl, benzyloxycarbonyl, p-nitrobenzyloxycarbonyl, o-bromobenzyloxycarbonyl, (mono-, di- and tri-)chloroacetyl, trifluoroacetyl, phenylacetyl, formyl, acetyl, benzoyl, tert-amyloxycarbonyl, tert-butoxycarbonyl, p-methoxybenzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl, 4-(phenylazo)benzyloxycarbonyl, 2-furfuryloxycarbonyl, diphenylmethoxycarbonyl, 1,1-dimethylpropoxycarbonyl, isopropoxycarbonyl, phthal
  • salts of the compounds of general formula [1] conventionally known salts formed at the position of basic group such as amino groups and the like and acidic group such as hydroxyl group, carboxyl group and the like can be referred to.
  • the salts formed at the position of basic group for example, salts formed with mineral acids such as hydrochloric acid, hydrobromic acid, sulfuric acid and the like; salts formed with organic carboxylic acids such as formic acid, acetic acid, citric acid, oxalic acid, fumaric acid, maleic acid, malic acid, tartaric acid, aspartic acid and the like; and salts formed with sulfonic acids such as methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, mesitylenesulfonic acid, naphthalenesulfonic acid and the like can be referred to.
  • salts formed at the position of acidic group for example, salts formed with an alkali metal such as sodium, potassium and the like; salts formed with an alkaline earth metal such as calcium, magnesium and the like; ammonium salts, salts formed with a nitrogen-containing organic base such as trimethylamine, triethylamine, tributylamine, pyridine, N,N-dimethylaniline, N-methylpiperidine, N-methylmorpholine, diethylamine, dicyclohexylamine, procaine, dibenzylamine, N-benzyl-beta-phenethylamine, 1-ephenamine, N,N′-dibenzylethylenediamine and the like; etc.
  • an alkali metal such as sodium, potassium and the like
  • salts formed with an alkaline earth metal such as calcium, magnesium and the like
  • ammonium salts, salts formed with a nitrogen-containing organic base such as trimethylamine, triethylamine, tributyl
  • alkyl ether derivatives of general formula [I] or salts thereof have isomers such as optical isomer, geometrical isomer, tautomer, etc.
  • the present invention involves all those isomers, and further involves hydrates, solvates and all the crystalline forms.
  • alkyl ether derivative or salt thereof used as the ingredient (A) compounds represented by general formula [1] in which the substituents are selected from the following combinations are preferable.
  • R 1 is a benzothienyl or benzofuranyl group which may be substituted with a group selected from halogen atoms, alkyl groups and phenyl group
  • R 2 is a hydroxyl group
  • R 3 is an alkyl group
  • R 4 is an alkyl group which may be substituted with an alkoxy-substituted phenyl group or R 3 and R 4 , taken in conjunction with a nitrogen atom to which R 3 and R 4 are linked, form a pyrrolidine ring, piperidine ring, piperazine ring or a morpholine ring
  • m is 1
  • n is 2.
  • R 1 is a benzothienyl or benzofuranyl group which may be substituted with a group selected from halogen atom, alkyl group optionally substituted with hydroxyl group, alkoxy group, carboxyl group, aminocarbonyl group, hydroxyl group, alkylthio group, phenyl group and pyridyl group;
  • R 2 is a hydrogen atom;
  • R 3 is an alkyl group which may be substituted with a group selected from phenyl group optionally substituted with halogen atom, alkoxy group or nitro group, optionally protected hydroxyl group, alkylamino group and alkynyl group;
  • R 4 is an alkyl group which may be substituted with a phenyl group;
  • a specific example of such a compound is 2-[[3-(2-benzo[b]thiophen-5-ylethoxy)propyl](methyl)amino]-1-ethanol.
  • R 1 is a benzothienyl or benzofuranyl group which may be substituted with a group selected from halogen atom, alkyl group and phenyl group
  • R 2 is a hydrogen atom
  • R 3 or R 4 is an alkyl group which may be substituted with hydroxyl group, optionally protected amino group and alkylamino group, or R 3 and R 4 represent an azetidine ring, a pyrrolidine ring, a piperidine ring, a piperazine ring or a morpholine ring which is formed by R 3 and R 4 together with the nitrogen atom to which R 3 and R 4 are linked
  • m is 1
  • n is 2 to 3.
  • alkyl ether derivatives of general formula [1] or salts thereof can be produced according to the method described in JP 3-47158A, JP 3-232830A, JP 4-95070A, WO99/31056, WO00/76957, PCT/JP02/10827, etc.
  • ingredient (B) As the compound having an acetylcholine esterase inhibiting activity used in this invention as ingredient (B), for example, the following can be referred to:
  • a pharmaceutical preparation such as tablet, capsule, powder, granule, fine granule, pill, suspension, emulsion, solution, syrup, injection, eye drop and the like can be formed in the usual manner by appropriately using pharmaceutically acceptable assistants such as excipient, carrier, diluent, stabilizer and the like.
  • the pharmaceutical preparation thus formed can be administered orally or non-orally.
  • the proportions of the ingredients (A) and (B) may be selected appropriately, the amount of ingredient (B) is 0.0005-1 part by weight per 1 part by weight of ingredient (A).
  • the amounts of ingredients (A) and (B) vary depending on the combination thereof, for example, the amount of ingredient (B) (the compound having an acetylcholine esterase inhibitory activity) may be an amount at which a reaction of the peripheral nervous symptom (predominantly, the reaction caused by the parasympathetic nervous system such as diarrhoea, lacrimmation, salivation, etc.) does not appear significantly.
  • the amount of ingredient (B) may be an amount at which a reaction of the peripheral nervous symptom (predominantly, the reaction caused by the parasympathetic nervous system such as diarrhoea, lacrimmation, salivation, etc.) does not appear significantly.
  • the amount is about 0.05 mg to 10 mg per day in the case of Donepezil, about 1 mg to 120 mg per day in the case of Zanapezil, about 5 mg to 200 mg per day in the case of Tacrine, about 10 mg to 300 mg per day in the case of Ipidacrine, and about 0.5 mg to 20 mg per day in the case of Rivastigmine.
  • ingredient (A) varies depending on the kind of ingredient (B), namely the compound having an acetylcholine esterase inhibitory activity, it is 0.01 to 500 mg per day.
  • Test compounds A1, A2, A3, B1 and B2 were put to use after dissolution in distilled water.
  • Test compounds C1 and C2 were put to use after suspending them in 0.5% solution of methylcellulose.
  • test was carried out according to the method described in Japanese Journal of Pharmacology, Vol. 62, Page 81, 1993.
  • mice To one group (6-10 animals) of ddY male mice having an age of 4-5 weeks was orally administered a test compound dissolved in distilled water or suspended in 0.5% methyl cellulose solution. Thirty minutes after the administration, the mice were introduced into a glass container at a volume of 300 mL, and a gaseous mixture composed of 4% of oxygen and 96% of nitrogen was passed though the glass container at a flow rate of 5 L/minute. The period of time from the start of passing the gaseous mixture to the death of the mice was measured. To the control group, distilled water was administered orally.
  • the anti-hypoxic activity of each test compound was calculated according to the following formula: (Survival time of mouse in the test compound ⁇ administered group/Survival time of mouse in the control group) ⁇ 100% The results are shown in Tables 1-3.
  • Anti-hypoxic activity can synergistically be improved by combining the alkyl ether derivative of general formula [1] or a salt thereof with a compound having an acetylcholine esterase inhibitory activity. Accordingly, the combination of this invention is useful as a method for improving the cerebral function.
  • a pharmaceutical composition containing the compound according to the combination of this invention is useful for treatment and prevention of dysfunction of cerebral acetylcholine neurons in the sequela of cerebrovascular dementia, senile dementia, Alzheimer's disease and ischemic cerebral lesion and in the cerebral apoplexy or the memory impairment caused by selective neuronal death.

Abstract

An alkyl ether derivative represented by the formula:
Figure USRE042327-20110503-C00001
wherein R1, R2, R3, R4, m and n are as defined in the specification, or salts thereof exhibits synergistically improved anti-hypoxic activity when combined with a compound having an acetylcholine esterase inhibitory activity. Therefore, the combination according to the present invention is useful as a method for improving cerebral function. Further, a pharmaceutical composition containing the compound relating to the combination according to the present invention is useful for treatment and prevention of dysfunction of cerebral acetylcholine neurons in the sequelae of cerebrovascular dementia, senile dementia, Alzheimer's disease and ischemic cerebral lesion and in the cerebral apoplexy or the memory impairment caused by selective neuronal death.

Description

This application is a 371 of PCT/JP03/04292 filed on Apr. 3, 2003.
TECHNICAL FIELD
This invention relates to a pharmaceutical composition for improving the cerebral function which contains an alkyl ether derivative and a compound having acetylcholine esterase inhibiting activity, and to a method using an alkyl ether derivative in combination with a compound having acetylcholine esterase inhibiting activity for the purpose of. improving the cerebral function.
BACKGROUND ART
It is generally said that, in the sequela of cereblovascular diseases or various neuronal degenerative diseases, the dysfunction of cerebral neurons and the cerebral neuronal death are in a close relation. Particularly in the sequelae of cerebrovascular dementia, senile dementia, Alzheimer's disease and ischemic cerebral lesion and in the cerebral apoplexy, there appears memory impairment caused by a dysfunction of in-brain acetylcholine neurons or a selective neuronal death.
As drugs for symptomatic treatment of this memory impairment, for example, compounds having an acetylcholine esterase inhibiting activity such as Tacrine, Donepezil, and the like are used.
On the other hand, the anti-hypoxic activity is used for evaluating the neuroprotective activity in-vitro, and it is reported that, in the in-vivo experiments, too, compounds having a neuroprotective activity show the same effect as above [Ann. N. Y. Acad. Sci., Vol. 890, Pages 406-420, 1999]. Further, it has been reported that the anti-hypoxic activity is shown by compounds activating the in-brain acetylcholine neurons and by Tacrine (1,2,3,4-tetrahydro-9-acridinamine hydrochloride) showing an acetylcholine esterase inhibiting activity [Jpn. J. Pharmacol., Vol. 62, Pages 81-86, 1993].
Accordingly, a work for studying the in-vivo anti-hypoxic activity can be regarded as a method for evaluating the compounds having one of the neuroprotective effect and the in-brain acetylcholine neurons activating effect or both of these effects.
The 1,2-ethanediol derivatives or salts thereof described in JP 3-232830A and JP 4-95070A are compounds useful as a cerebral function-improving agent, and particularly (R)-1-{benzo[b]thiophen-5-yl}-2-[2-(N,N-diethylamino}ethoxy]ethanol hydrochloride (hereinafter, referred to as T-588) is a preferable compound. It has been reported that T-588 has an anti-hypoxic activity and an anti-amnestic activity, and promotes the release of in-brain acetylcholine (SOCIETY FOR NEUROSCIENCE, Abstracts, Vol. 21, Page 947, 1995). It is also known that T-588 exhibits a protecting effect on the neuronal death caused by amyloid-beta-protein (SOCIETY FOR NEUROSCIENCE, Abstracts, Vol. 24, Part 1, Page 228, 1998) and that T-588 exhibits an increasing effect on the action of nerve growth factor (WO96/12717). However, nothing has ever been reported with regard to the cerebral function improving action of T-588 and particularly to chemicals and method for improving the anti-hypoxic action thereof.
At the present time, compounds having a neuroprotective activity are being studied from the viewpoint of preventing the dysfunction of in-brain acetylcholine neurons or the selective neuronal death in the sequela of cerebrovascular dementia, senile dementia, Alzheimer's disease and ischemic cerebral lesion and in the cerebral apoplexy. However, the therapeutic effect of these compounds are not yet well known. Although acetylcholine esterase inhibiting drugs such as Tacrine, Donepezil, Galanthamine, and the like are commercially available as cerebral function-improving drugs including Alzheimer's disease-curing drug, these drugs have problems in the point of side-reactions because some of them have a hepatic toxicity and some others have a side reaction accompanied by activation of acetylcholine neurons other than central nervous system. Thus, for the purpose of lightening the side reaction of acetylcholine esterase inhibiting drugs, for example, a combination of a brain circulation metabolism improver such as Idebenone and an acetylcholine esterase inhibitor (JP 10-259126A) or a combination of a compound having a nerve growth factor-like activity (SR57746A) and an acetylcholine esterase inhibitor (WO99/25363), etc. are being attempted.
DISCLOSURE OF THE INVENTION
After extensive studies, the present inventors have found that the anti-hypoxic activity can synergistically be improved by using a compound having an acetylcholine esterase inhibiting activity in combination with an alkyl ether derivative represented by the following formula [1]:
Figure USRE042327-20110503-C00002
wherein R1 represents a substituted or unsubstituted heterocyclic group; R2 represents a hydrogen atom or a hydroxyl group; R3 and R4 which may be the same or different, each represents a substituted or unsubstituted alkyl, or R3 and R4, taken together with the nitrogen atom to which they are linked, form a substituted or unsubstituted cyclic amino group; m represents an integer of 1 to 5; and n represents an integer of 1 to 6; or a salt thereof, including T-588. Based on the knowledge that the combination of an alkyl ether derivative of formula [1] or a salt thereof and a compound having acetylcholine esterase inhibiting activity is useful as a method for improving the cerebral function, the present invention has been accomplished.
Next, the present invention will be explained in detail.
Unless otherwise referred to, the technical terms used in this specification have the following meanings. Halogen atom means a fluorine atom, a chlorine atom, a bromine atom or an iodine atom; alkyl group means a straight chain or branched chain C1-12 alkyl group such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, heptyl, octyl and the like; lower alkyl group means a straight chain or branched chain C1-6 alkyl group such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl and the like; alkoxy group means a straight or branched chain C1-12 alkyloxy group such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, tert-butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy and the like; lower alkyloxy group means a straight chain or branched chain C1-6 alkyloxy group such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, tert-butoxy, pentyloxy, hexyloxy and the like; alkenyl group means a C2-12 alkenyl group such as vinyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl and the like; lower alkenyl group means a C2-6 alkenyl group such as vinyl, propenyl, butenyl, pentenyl, hexenyl and the like; alkenyloxy group means C2-12 alkenyloxy group such as vinyloxy, propenyloxy, butenyloxy, pentenyloxy, hexenyloxy, heptenyloxy, octenyloxy and the like; lower alkenyloxy group means C2-6 alkenyloxy group such as vinyloxy, propenyloxy, butenyloxy, pentenyloxy, hexenyloxy and the like; alkynyl group means C2-6 alkynyl group such as ethynyl, propynyl, butynyl, pentynyl and the like; cycloalkyl group means cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl groups; alkylthio group means C1-12 alkylthio groups such as methylthio, ethylthio, propylthio, isopropylthio, butylthio, isobutylthio, tert-butylthio, pentylthio, hexylthio, heptylthio, octylthio and the like; lower alkylthio group means C1-6 alkylthio groups such as methylthio, ethylthio, propylthio, isopropylthio, butylthio, isobutylthio, tert-butylthio, pentylthio, hexylthio and the like; aryl group means phenyl, naphthyl, indanyl and indenyl; aryloxy group means phenyloxy, naphthyloxy, indanyloxy and indenyloxy groups; ar-lower alkyl group means ar-C1-6 alkyl groups such as benzyl, diphenylmethyl, phenethyl and the like; ar-lower alkenyl group means ar-C2-6 alkenyl groups such as cinnamyl and the like; ar-lower alkoxy group means ar-C1-6 alkoxy group such as phenylmethyloxy, naphthylmethyloxy and the like; ar-lower alkylthio group means ar-C1-6 alkylthio groups such as phenylmethylthio, naphthylmethylthio and the like; lower alkylenedioxy group means C1-6 alkylenedioxy group such as methylenedioxy, ethylenedioxy and the like; lower acyl group means C1-6 acyl groups such as formyl, acetyl, ethylcarbonyl and the like; aroyl group means arylcarbonyl groups such as benzoyl, naphthylcarbonyl and the like; ar-lower alkenoyl group means ar-C2-6 alkenoyl groups such as cinnamoyl and the like; lower alkylsulfonyl group means C1-6 alkylsulfonyl groups such as methylsulfonyl, ethylsulfonyl, n-propylsulfonyl, isopropylsulfonyl, n-butylsulfonyl, isobutylsulfonyl, sec-butylsulfonyl, tert-butylsulfonyl, pentylsulfonyl and the like; arylsulfonyl group means phenylsulfonyl, p-toluenesulfonyl, naphthylsulfonyl and the like; lower alkylsulfonyloxy group means C1-6 alkylsulfonyloxy groups methylsulfonyloxy, ethylsulfonyloxy, n-propylsulfonyloxy, isopropylsulfonyloxy, n-butylsulfonyloxy, isobutylsulfonyloxy, sec-butylsulfonyloxy, tert-butylsulfonyloxy, pentylsulfonyloxy and the like; arylsulfonyloxy group means phenylsulfonyloxy, p-toluenesulfonyloxy, naphthylsulfonyloxy groups and the like; ar-lower alkylsulfonyl group means ar-C1-6 alkylsulfonyl groups such as benzylsulfonyl and the like; lower alkylsulfonylamino group means C1-6 alkylsulfonylamino groups such as methylsulfonylamino, ethylsulfonylamino, propylsulfonylamino and the like; arylsulfonylamino group means phenylsulfonylamino, p-toluenesulfonylamino and naphthylsulfonylamino groups and the like; cyclic amino group means cyclic amino groups having 4-7 membered cycle, fused cycle or crosslinked cycle which contains at least one nitrogen atom as a hetero-atom constituting said ring and may additionally contain at least one oxygen atom or sulfur atom, such as azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, homopiperidinyl, morpholyl, thiomorpholyl, tetrahydroquinolinyl, tetrahydroisoquinolyl, quinuclidinyl, imidazolinyl and the like; heterocyclic group means the above-mentioned cyclic amino groups and, in addition, heterocyclic groups which may contain at least one hetero-atom selected from nitrogen, oxygen and sulfur atoms as a hetero-atom constituting said ring and have at least one 5- or 6-membered ring structure or a fused ring structure or a crosslinked ring structure, such as pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrimidyl, quinolyl, quinolizinyl, thiazolyl, tetrazolyl, thiadiazolyl, pyrrolinyl, pyrazolinyl, pyrazolidinyl, purinyl, furyl, thienyl, benzothienyl, pyranyl, isobenzofuranyl, oxazolyl, isoxazolyl, benzofuranyl, indolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, quinoxalyl, dihydroquinoxalyl, 2,3-dihydrobenzothienyl, 2,3-dihydrobenzopyrrolyl, 2,3-4H-1-thianaphthyl, 2,3-dihydrobenzofuranyl, benzo[b]dioxanyl, imidazo[2,3-a]pyridyl, benzo[b]piperazinyl, chromenyl, isothiazolyl, isoxazolyl, oxadiazolyl, pyridazinyl, isoindolyl, isoquinolyl, 1,3-benzodioxolyl, 1,4-benodioxanyl and the like; and nitrogen-containing saturated 6-membered heterocyclic ring means saturated 6-membered rings containing nitrogen atom as a hetero-atom, such as piperidine, piperazine, perhydropyrimidine, perhydropyridazine and the like.
The heterocyclic group of R1 may be substituted with at least one residue selected from halogen atom, optionally substituted amino, lower alkyl, aryl, ar-lower alkyl, lower alkoxy, ar-lower alkoxy, aryloxy, carbamoyloxy, lower alkylthio, lower alkenyl, lower alkenyloxy, ar-lower alkylthio, ar-lower alkylsulfonyl, arylsulfonyl, lower alkylsulfonylamino, arylsulfonylamino groups, or optionally protected amino group, optionally protected hydroxyl group, nitro group, heterocyclic group, oxo group, lower alkylenedioxy group and the like.
The amino groups of R3 and R4 and the cyclic amino group which R3 and R4 form in conjunction with the nitrogen atom to which R3 and R4 are linked may be substituted with at least one group selected from halogen atom, optionally substituted amino group, lower alkyl group, aryl group, ar-lower alkyl group, ar-lower alkenyl group, aroyl group, ar-lower alkenoyl group, heterocyclic group and the like.
The substituents in the above-mentioned R1, R3, R4 and the cyclic amino group which R3 and R4 form in conjunction with the nitrogen atom to which R3 and R4 and linked may further be substituted with at least one group selected from halogen atom, optionally protected hydroxyl group, optionally protected carboxyl group, optionally protected amino group, lower alkyl group, lower alkoxy group, lower acyl group, cycloalkyl group, ar-lower alkyl group and the like.
The protecting group for carboxyl group includes all the residues which can conventionally be used as a protecting group for carboxyl group, of which examples include lower alkyl groups such as methyl, ethyl, propyl, isopropyl, 1,1-dimethylpropyl, butyl, tert-butyl and the like; aryl groups such as phenyl, naphthyl and the like; ar-lower alkyl groups such as benzyl, diphenylmethyl, trityl, p-nitrobenzyl, p-methoxybenzyl, bis(p-methoxyphenyl)methyl and the like; acyl-lower alkyl groups such as acetylmethyl, benzoylmethyl, p-nitrobenzoylmethyl, p-bromobenzoylmethyl, p-methanesulfonylbenzoylmethyl and the like; oxygen-containing heterocyclic groups such as 2-tetrahydropyranyl, 2-tetrahydrofuranyl and the like; halogeno-lower alkyl groups such as 2,2,2-trichloroethyl and the like; lower alkylsilyl-lower alkyl groups such as 2-(trimethylsilyl)ethyl and the like; acyloxy-lower alkyl groups such as acetoxymethyl, propionyloxymethyl, pivaloyloxymethyl and the like; nitrogen-containing heterocycle-lower alkyl groups such as phthalimidomethyl, succinimidomethyl and the like; cycloalkyl groups such as cyclohexyl and the like; lower alkoxy-lower alkyl groups such as methoxymethyl, methoxyethoxymethyl, 2-(trimethylsilyl)ethoxymethyl and the like; ar-lower alkoxy-lower alkyl groups such as benzyloxymethyl and the like; lower alkylthio-lower alkyl groups such as methylthiomethyl, 2-methylthioethyl and the like; arylthio-lower alkyl groups such as phenylthiomethyl and the like; lower alkenyl groups such as 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl and the like; substituted silyl groups such as trimethylsilyl, triethylsilyl, triisopropylsilyl, diethylisopropylsilyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, diphenylmethylsilyl, tert-butylmethoxyphenylsilyl and the like; etc.
The protecting group for hydroxyl group include all the residues which can conventionally be used for protection of hydroxyl group, of which examples include acyl groups such as benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl, methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, 1,1-dimethylpropoxycarbonyl, isopropoxycarbonyl, isobutyloxycarbonyl, diphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2,2,2-tribromoethoxycarbonyl, 2-(trimethylsilyl)-ethoxycarbonyl, 2-(phenylsulfonyl)ethoxycarbonyl, 2-(triphenylphosphonio)ethoxycarbonyl, 2-furfuryloxycarbonyl, 1-adamantyloxycarbonyl, vinyloxycarbonyl, allyloxycarbonyl, S-benzylthiocarbonyl, 4-ethoxy-1-naphthyloxycarbonyl, 8-quinolyloxycarbonyl, acetyl, formyl, chloroacetyl, dichloroacetyl, trichloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, pivaloyl, benzoyl and the like; lower alkyl groups such as methyl, tert-butyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl and the like; lower alkenyl groups such as allyl and the like; ar-lower alkyl groups such as benzyl, p-methoxybenzyl, 3,4-dimethoxybenzyl, diphenylmethyl, trityl and the like; oxygen-containing and sulfur-containing heterocyclic groups such as tetrahydrofuryl, tetrahydropyranyl, tetrahydrothiopyranyl and the like; lower alkoxy- and lower alkylthio-lower alkyl groups such as methoxymethyl, methylthiomethyl, benzyloxymethyl, 2-methoxyethoxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, 1-ethoxyethyl, 1-methyl-1-methoxyethyl and the like; lower alkyl- and aryl-sulfonyl groups such as methanesulfonyl, p-toluenesulfonyl and the like; substituted silyl groups such as trimethylsilyl, triethylsilyl, triisopropylsilyl, diethylisopropylsilyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, diphenylmethylsilyl, tert-butylmethoxyphenylsilyl and the like; etc.
The protecting group for amino group include all the residues which can conventionally be used as a protecting group for amino groups, of which examples include acyl groups such as trichloroethoxycarbonyl, tribromoethoxycarbonyl, benzyloxycarbonyl, p-nitrobenzyloxycarbonyl, o-bromobenzyloxycarbonyl, (mono-, di- and tri-)chloroacetyl, trifluoroacetyl, phenylacetyl, formyl, acetyl, benzoyl, tert-amyloxycarbonyl, tert-butoxycarbonyl, p-methoxybenzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl, 4-(phenylazo)benzyloxycarbonyl, 2-furfuryloxycarbonyl, diphenylmethoxycarbonyl, 1,1-dimethylpropoxycarbonyl, isopropoxycarbonyl, phthaloyl, succinyl, alanyl, leucyl, 1-adamantyloxycarbonyl, 8-quinolyloxycarbonyl and the like; ar-lower alkyl groups such as benzyl, diphenylmethyl, trityl and the like; arylthio groups such as 2-nitrophenylthio, 2,4-dinitrophenylthio and the like; alkyl- or aryl-sulfonyl groups such as methanesulfonyl, p-toluenesulfonyl and the like; di-lower alkylamino-lower alkylidene groups such as N,N-dimethylaminomethylene and the like; ar-lower alkylidene groups such as benzylidene, 2-hydroxybenzylidene, 2-hydroxy-5-chlorobenzylidene, 2-hydroxy-1-naphthylmethylene and the like; nitrogen-containing heterocycle-alkylidene groups such as 3-hydroxy-4-pyridylmethylene and the like; cycloalkylidene groups such as cyclohexylidene, 2-ethoxycarbonylcyclohexylidene, 2-ethoxycarbonylcyclopentylidene, 2-acetylcyclohexylidene, 3,3-dimethyl-5-oxycyclohexylidene and the like; diaryl- or diar-lower alkyl phosphoryl groups such as diphenylphosphoryl, dibenzylphosphoryl and the like; oxygen-containing heterocyclic alkyl groups such as 5-methyl-2-oxo-2H-1,3-dioxol-4-ylmethyl and like; substituted silyl groups such as trimethylsilyl and the like; etc.
As salts of the compounds of general formula [1], conventionally known salts formed at the position of basic group such as amino groups and the like and acidic group such as hydroxyl group, carboxyl group and the like can be referred to. As the salts formed at the position of basic group, for example, salts formed with mineral acids such as hydrochloric acid, hydrobromic acid, sulfuric acid and the like; salts formed with organic carboxylic acids such as formic acid, acetic acid, citric acid, oxalic acid, fumaric acid, maleic acid, malic acid, tartaric acid, aspartic acid and the like; and salts formed with sulfonic acids such as methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, mesitylenesulfonic acid, naphthalenesulfonic acid and the like can be referred to. As the salts formed at the position of acidic group, for example, salts formed with an alkali metal such as sodium, potassium and the like; salts formed with an alkaline earth metal such as calcium, magnesium and the like; ammonium salts, salts formed with a nitrogen-containing organic base such as trimethylamine, triethylamine, tributylamine, pyridine, N,N-dimethylaniline, N-methylpiperidine, N-methylmorpholine, diethylamine, dicyclohexylamine, procaine, dibenzylamine, N-benzyl-beta-phenethylamine, 1-ephenamine, N,N′-dibenzylethylenediamine and the like; etc.
Some of the alkyl ether derivatives of general formula [I] or salts thereof have isomers such as optical isomer, geometrical isomer, tautomer, etc. In such cases, the present invention involves all those isomers, and further involves hydrates, solvates and all the crystalline forms.
As the alkyl ether derivative or salt thereof used as the ingredient (A), compounds represented by general formula [1] in which the substituents are selected from the following combinations are preferable.
(1) Alkyl ether derivatives or salts thereof in which R1 is a benzothienyl or benzofuranyl group which may be substituted with a group selected from halogen atoms, alkyl groups and phenyl group; R2 is a hydroxyl group; R3 is an alkyl group; R4 is an alkyl group which may be substituted with an alkoxy-substituted phenyl group or R3 and R4, taken in conjunction with a nitrogen atom to which R3 and R4 are linked, form a pyrrolidine ring, piperidine ring, piperazine ring or a morpholine ring; m is 1; and n is 2.
A specific example of such a compound is (benzo[b]thiophen-5-yl)-2-[2-(N,N-diethylamino)ethoxy]ethanol.
(2) Alkyl ether derivatives or salts thereof in which R1 is a benzothienyl or benzofuranyl group which may be substituted with a group selected from halogen atom, alkyl group optionally substituted with hydroxyl group, alkoxy group, carboxyl group, aminocarbonyl group, hydroxyl group, alkylthio group, phenyl group and pyridyl group; R2 is a hydrogen atom; R3 is an alkyl group which may be substituted with a group selected from phenyl group optionally substituted with halogen atom, alkoxy group or nitro group, optionally protected hydroxyl group, alkylamino group and alkynyl group; R4 is an alkyl group which may be substituted with a phenyl group; m is 1; and n is 2 to 3.
A specific example of such a compound is 2-[[3-(2-benzo[b]thiophen-5-ylethoxy)propyl](methyl)amino]-1-ethanol.
(3) Alkyl ether derivatives or salts thereof in which R1 is a benzothienyl or benzofuranyl group which may be substituted with a group selected from halogen atom, alkyl group and phenyl group; R2 is a hydrogen atom; R3 or R4 is an alkyl group which may be substituted with hydroxyl group, optionally protected amino group and alkylamino group, or R3 and R4 represent an azetidine ring, a pyrrolidine ring, a piperidine ring, a piperazine ring or a morpholine ring which is formed by R3 and R4 together with the nitrogen atom to which R3 and R4 are linked; m is 1; and n is 2 to 3.
An example of such a compound is 1-[2-[2-(1-benzothiophen-5-yl(ethoxy]ethyl]-3-azetidinol.
The alkyl ether derivatives of general formula [1] or salts thereof can be produced according to the method described in JP 3-47158A, JP 3-232830A, JP 4-95070A, WO99/31056, WO00/76957, PCT/JP02/10827, etc.
As the compound having an acetylcholine esterase inhibiting activity used in this invention as ingredient (B), for example, the following can be referred to:
  • Tacrine; the compounds described in JP 1-79151A represented by Donepezil; the compounds described in JP 61-225158A represented by Rivastigmine; the compounds described in JP 62-215527A represented by Galanthamine; the compounds described in U.S. Pat. No. 5,177,082 represented by Huperzine; Ipidacrine; the compounds described in JP 5-140149A represented by Zanapezil; Phenserine; Quilostigmine; Ganstigmine; the compounds described in WO92/18493 represented by Ensaculin; the compounds described in JP 5-279355A represented by T-82; and the like. Among these compounds, those further preferable as ingredient (B) are Tacrine and Donepezil.
In making a pharmaceutical preparation from a composition comprising the alkyl ether derivative of general formula [1] or a salt thereof and a compound having an acetylcholine esterase inhibiting activity or a salt thereof, a pharmaceutical preparation such as tablet, capsule, powder, granule, fine granule, pill, suspension, emulsion, solution, syrup, injection, eye drop and the like can be formed in the usual manner by appropriately using pharmaceutically acceptable assistants such as excipient, carrier, diluent, stabilizer and the like. The pharmaceutical preparation thus formed can be administered orally or non-orally. Although the method of administration, the dosage of administration and the frequency of administration can be appropriately selected in accordance with age, body weight and symptom of the patient, it is conventional in the case of oral administration to an adult person to administer 0.01-500 mg in one to several portions per day.
Although the proportions of the ingredients (A) and (B) may be selected appropriately, the amount of ingredient (B) is 0.0005-1 part by weight per 1 part by weight of ingredient (A).
Although the amounts of ingredients (A) and (B) vary depending on the combination thereof, for example, the amount of ingredient (B) (the compound having an acetylcholine esterase inhibitory activity) may be an amount at which a reaction of the peripheral nervous symptom (predominantly, the reaction caused by the parasympathetic nervous system such as diarrhoea, lacrimmation, salivation, etc.) does not appear significantly. For example, the amount is about 0.05 mg to 10 mg per day in the case of Donepezil, about 1 mg to 120 mg per day in the case of Zanapezil, about 5 mg to 200 mg per day in the case of Tacrine, about 10 mg to 300 mg per day in the case of Ipidacrine, and about 0.5 mg to 20 mg per day in the case of Rivastigmine.
Although the amount of ingredient (A) varies depending on the kind of ingredient (B), namely the compound having an acetylcholine esterase inhibitory activity, it is 0.01 to 500 mg per day.
EXAMPLES
Next, the activating and protecting actions on neurons brought about by combination of an alkyl ether derivative of general formula [1] or a salt thereof and a compound having an acetylcholine esterase inhibiting activity will be mentioned.
  • Anti-Hypoxic Activity
  • Compound A1: T-588
  • Compound A2: 2-[[3-(2-benzo[b]thiophen-5-yl-ethoxy)propyl](methyl)amino]-1-ethanol.1/2fumarate
  • Compound A3: 1-[3-(2-(1-benzothiophen-5-yl)ethoxy)-propyl]-3-azetidinol.maleate
  • Compound B1: Donepezil
  • Compound B2: Tacrine
  • Compound C1: Idebenone
  • Compound C2: SR57746A
Test compounds A1, A2, A3, B1 and B2 were put to use after dissolution in distilled water. Test compounds C1 and C2 were put to use after suspending them in 0.5% solution of methylcellulose.
(Testing Method)
The test was carried out according to the method described in Japanese Journal of Pharmacology, Vol. 62, Page 81, 1993.
To one group (6-10 animals) of ddY male mice having an age of 4-5 weeks was orally administered a test compound dissolved in distilled water or suspended in 0.5% methyl cellulose solution. Thirty minutes after the administration, the mice were introduced into a glass container at a volume of 300 mL, and a gaseous mixture composed of 4% of oxygen and 96% of nitrogen was passed though the glass container at a flow rate of 5 L/minute. The period of time from the start of passing the gaseous mixture to the death of the mice was measured. To the control group, distilled water was administered orally.
The anti-hypoxic activity of each test compound was calculated according to the following formula:
(Survival time of mouse in the test compound−administered group/Survival time of mouse in the control group)×100%
The results are shown in Tables 1-3.
TABLE 1
Dosage Dosage Anti-hypoxic
Compound (1) (mg/kg) Compound (2) (mg/kg) activity (%)
Control — — — 100
Compound A1 10 — — 137
Compound B1 3 — — 119
Compound B2 10 — — 127
Compound A1 10 Compound B1 3 211
Compound A1 10 Compound B2 10 172
TABLE 2
Dosage Dosage Anti-hypoxic
Compound (1) (mg/kg) Compound (2) (mg/kg) activity (%)
Control — — — 100
Compound A2 10 — — 114
Compound A3 10 — — 111
Compound B1 3 — — 104
Compound B2 10 — — 107
Compound A2 10 Compound B1 3 168
Compound A2 10 Compound B2 10 172
Compound A3 10 Compound B1 3 190
Compound A3 10 Compound B2 10 149
TABLE 3
Dosage Dosage Anti-hypoxic
Compound (1) (mg/kg) Compound (2) (mg/kg) activity (%)
Control — — — 100
Compound C1 100 — — 104
Compound C1 300 — — 108
Compound C1 300 Compound B1 3 100
Compound C2 30 — — 100
Compound C2 100 — — 123
Compound C2 100 Compound B1 3 111
INDUSTRIAL APPLICABILITY
Anti-hypoxic activity can synergistically be improved by combining the alkyl ether derivative of general formula [1] or a salt thereof with a compound having an acetylcholine esterase inhibitory activity. Accordingly, the combination of this invention is useful as a method for improving the cerebral function. A pharmaceutical composition containing the compound according to the combination of this invention is useful for treatment and prevention of dysfunction of cerebral acetylcholine neurons in the sequela of cerebrovascular dementia, senile dementia, Alzheimer's disease and ischemic cerebral lesion and in the cerebral apoplexy or the memory impairment caused by selective neuronal death.

Claims (12)

1. A pharmaceutical composition comprising the following ingredients (A) and (B):
Ingredient (A): An alkyl ether derivative represented by the following formula:
Figure USRE042327-20110503-C00003
wherein R1 represents a benzothienyl group which may be substituted with a group selected from a halogen atom, an alkyl group, and a phenyl group; R2 represents a hydrogen atom; R3 and R4, each represents an alkyl group, or R3 and R4, taken conjointly with the nitrogen atom to which R3 and R4 are linked, form an azetidine ring; m represents 1; and n represents 2 to 3; or a salt thereof,
Ingredient (B): A compound selected from the group consisting of Donepezil and Tacrine.
2. A method of preparing a medicament comprising combining the following ingredients (A) and (B),
Ingredient (A): An alkyl ether derivative represented by the following formula:
Figure USRE042327-20110503-C00004
wherein R1 represents a benzothienyl group which may be substituted with a group selected from a halogen atom, an alkyl group, and a phenyl group; R2 represents a hydrogen atom; R3 and R4, each represents an alkyl group, or R3 and R4, taken conjointly with the nitrogen atom to which R3 and R4 are linked, form an azetidine ring; m represents; and n represents 2 to 3; or a salt thereof,
Ingredient (B): A compound selected from the group consisting of Donepezil and Tacrine.
3. A pharmaceutical composition as claimed in claim 1 wherein the pharmaceutical composition is administered to a patient to treat Alzheimer's disease.
4. A method of treating Alzheimer's disease comprising administering the pharmaceutical composition of claim 1 to a patient in need thereof.
5. The pharmaceutical composition as claimed in claim 1 9, wherein said ingredient (A) is 1-[3-(2-(1-benzothiophen-5-yl)ethoxy)propyl]-3-azetidinol.or 1-[3-(2-(1-benzothiophen-5-yl)ethoxy)propyl]-3-azetidinol or a salt thereof.
6. The pharmaceutical composition as claimed in claim 1 9, wherein said ingredient (A) is 1-[3-(2-(1-benzothiophen-5-yl)ethoxy)propyl]-3-azetidinol.maleate 1-[3-(2-(1-benzothiophen-5-yl)ethoxy)propyl]-3-azetidinol maleate.
7. The method as claimed in claim 2 10, wherein said ingredient (A) is 1-[3-(2-(1-benzothiophen-5-yl)ethoxy)propyl]-3-azetidinol.or 1-[3-(2-(1-benzothiophen-5-yl)ethoxy)propyl]-3-azetidinol or a salt thereof.
8. The method as claimed in claim 2 10, wherein said ingredient (A) is 1-[3-(2-(1-benzothiophen-5-yl)ethoxy)propyl]-3-azetidinolmaleate 1-[3-(2-(1-benzothiophen-5-yl)ethoxy)propyl]-3-azetidinol maleate.
9. A pharmaceutical composition comprising the following ingredients (A) and (B):
Ingredient (A): An alkyl ether derivative represented by the following formula:
Figure USRE042327-20110503-C00005
 wherein R1 represents a benzothienyl group which may be substituted with a group selected from a halogen atom, an alkyl group, and a phenyl group; R2 represents a hydrogen atom; R3 and R4, taken conjointly with the nitrogen atom to which R3 and R4 are linked, form an azetidine ring which may be substituted by a hydroxyl group; m represents 1; and n represents 2 to 3; or a salt thereof,
Ingredient (B): A compound selected from the group consisting of Donepezil and Tacrine.
10. A method of preparing a medicament comprising combining the following ingredients (A) and (B),
Ingredient (A): An alkyl ether derivative represented by the following formula:
Figure USRE042327-20110503-C00006
 wherein R1 represents a benzothienyl group which may be substituted with a group selected from a halogen atom, an alkyl group, and a phenyl group; R2 represents a hydrogen atom; R3 and R4, taken conjointly with the nitrogen atom to which R3 and R4 are linked, form an azetidine ring which may be substituted by a hydroxyl group; m represents 1; and n represents 2 to 3; or a salt thereof,
Ingredient (B): A compound selected from the group consisting of Donepezil and Tacrine.
11. A pharmaceutical composition as claimed in claim 9, wherein the pharmaceutical composition is administered to a patient to treat Alzheimer's disease.
12. A method of treating Alzheimer's disease comprising administering the pharmaceutical composition of claim 9 to a patient in need thereof.
US12/683,813 2002-06-14 2003-04-03 Medicinal compositions improving brain function and method for improving brain function Expired - Lifetime USRE42327E1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002-173483 2002-06-14
JP2002173483 2002-06-14
PCT/JP2003/004292 WO2003105830A1 (en) 2002-06-14 2003-04-03 Medicinal compositions improving brain function and method for improving brain function

Publications (1)

Publication Number Publication Date
USRE42327E1 true USRE42327E1 (en) 2011-05-03

Family

ID=29727916

Family Applications (3)

Application Number Title Priority Date Filing Date
US12/683,813 Expired - Lifetime USRE42327E1 (en) 2002-06-14 2003-04-03 Medicinal compositions improving brain function and method for improving brain function
US10/516,320 Ceased US7342043B2 (en) 2002-06-14 2003-04-03 Medicinal compositions improving brain function and method for improving brain function
US11/957,832 Expired - Lifetime US7834053B2 (en) 2002-06-14 2007-12-17 Medicinal compositions improving brain function and method for improving brain function

Family Applications After (2)

Application Number Title Priority Date Filing Date
US10/516,320 Ceased US7342043B2 (en) 2002-06-14 2003-04-03 Medicinal compositions improving brain function and method for improving brain function
US11/957,832 Expired - Lifetime US7834053B2 (en) 2002-06-14 2007-12-17 Medicinal compositions improving brain function and method for improving brain function

Country Status (23)

Country Link
US (3) USRE42327E1 (en)
EP (2) EP2389937B1 (en)
JP (1) JP4675103B2 (en)
KR (1) KR100935615B1 (en)
CN (1) CN100375619C (en)
AT (1) ATE546140T1 (en)
AU (1) AU2003236364C1 (en)
BR (1) BRPI0311780B8 (en)
CA (1) CA2488120C (en)
CY (2) CY1112958T1 (en)
DK (2) DK1514542T3 (en)
ES (2) ES2685923T3 (en)
HU (1) HUE041842T2 (en)
IL (1) IL165589A (en)
MX (1) MXPA04012534A (en)
NO (1) NO333504B1 (en)
NZ (1) NZ537090A (en)
PL (1) PL217394B1 (en)
PT (2) PT2389937T (en)
SI (2) SI1514542T1 (en)
TR (1) TR201816386T4 (en)
WO (1) WO2003105830A1 (en)
ZA (1) ZA200409901B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE43676E1 (en) 2001-10-19 2012-09-18 Toyama Chemical Co., Ltd. Alkyl ether derivatives or salts thereof

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2389937T (en) 2002-06-14 2018-10-26 Toyama Chemical Co Ltd Medicinal composition for improving brain function
US20060205709A1 (en) * 2003-04-17 2006-09-14 Toyama Chemical Co., Ltd. Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof
US7435837B2 (en) 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
EP2258357A3 (en) * 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
JP5695293B2 (en) * 2006-04-26 2015-04-01 富山化学工業株式会社 Neuronal neurogenesis-inducing agent and psychiatric disorder therapeutic agent containing alkyl ether derivative or salt thereof
US8119625B2 (en) * 2006-04-26 2012-02-21 Toyama Chemical Co., Ltd. Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof
PT2048145E (en) * 2006-08-04 2011-01-14 Toyama Chemical Co Ltd Protein kinase c activity enhancer containing alkyl ether derivative or salt thereof
US20090221554A1 (en) * 2008-02-28 2009-09-03 Zenyaku Kogyo Kabushiki Kaisha Method of treating cognitive impairment
BRPI0912266B8 (en) * 2008-05-28 2021-05-25 Toyama Chemical Co Ltd compound derived from benzothiophene oxide, and, pharmaceutical composition
EP2885267B1 (en) 2012-07-12 2018-09-05 Concert Pharmaceuticals, Inc. Deuterated idebenone
SI3100725T1 (en) * 2014-01-31 2020-08-31 Fujifilm Toyama Chemical Co., Ltd. Post nerve injury rehabilitation effect-enhancing agent comprising an alkyl ether derivative or a salt thereof
KR20190141762A (en) 2017-06-02 2019-12-24 후지필름 도야마 케미컬 가부시키가이샤 Prevention or treatment of tau disease
US11666551B2 (en) 2017-06-02 2023-06-06 Fujifilm Toyama Chemical Co., Ltd. Agent for reducing amount of amyloid β protein
AU2018277981B2 (en) * 2017-06-02 2021-04-08 Fujifilm Toyama Chemical Co., Ltd. Agent for preventing or treating spinocerebellar ataxia
CN116473962A (en) * 2017-06-02 2023-07-25 富士胶片富山化学株式会社 Agent for preventing or treating brain atrophy
US11541033B2 (en) 2017-06-02 2023-01-03 Fujifilm Toyama Chemical Co., Ltd. Agent for preventing or treating Alzheimer's disease
CA3068938A1 (en) * 2017-07-08 2019-01-17 The General Hospital Corporation Screening platform to identify therapeutic drugs or agents for treatment of alzheimer's disease
US11548878B2 (en) 2017-10-30 2023-01-10 Fujifilm Toyama Chemical Co., Ltd. Emopamil binding protein binding agent and use thereof
CN110464834B (en) * 2019-09-04 2022-12-02 北京豪思生物科技股份有限公司 Application of ceruloplasmin and donepezil combined
KR20220040291A (en) 2020-09-23 2022-03-30 씨엔지바이오 주식회사 4-methoxy-2-phenethylisoindolin-1-one derivatives and a composition for treatment of neurological diseases comprising the same
KR20220040294A (en) 2020-09-23 2022-03-30 씨엔지바이오 주식회사 6-methoxy-2-phenethylisoindolin-1-one derivatives and a composition for treatment of neurological diseases comprising the same

Citations (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61225158A (en) 1985-03-05 1986-10-06 プロテ−ラ・アクチエンゲゼルシャフト Phenylcarbamates
JPS62215527A (en) 1986-01-15 1987-09-22 ボニ−、デイビス Alzheimer's sclerosis remedy
JPS6479151A (en) 1987-06-22 1989-03-24 Eisai Co Ltd Cyclic amine derivative
JPH0210827A (en) 1988-06-29 1990-01-16 Matsushita Electron Corp Manufacture of semiconductor device
EP0383281A1 (en) 1989-02-14 1990-08-22 Toyama Chemical Co., Ltd. 1,2-ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same
JPH0347158A (en) 1989-04-26 1991-02-28 Toyama Chem Co Ltd 1,2-ethanediol derivative and salt thereof
JPH03232830A (en) 1990-02-05 1991-10-16 Toyama Chem Co Ltd 1,2-ethanediol derivative and its salt
US5081117A (en) * 1989-09-28 1992-01-14 Hoechst-Roussel Pharmaceuticals Incorporated 4- and 6-carbamates related to physostigmine and intermediates for the preparation thereof
JPH0495070A (en) 1990-08-09 1992-03-27 Toyama Chem Co Ltd 1,2-ethandiol derivative and salt of same derivative
WO1992018493A1 (en) 1991-04-11 1992-10-29 Dr. Willmar Schwabe Gmbh & Co. Benzopyranones, methods of manufacture and use thereof
US5177082A (en) 1985-11-05 1993-01-05 Yu Chao Mei Huperzines and analogs
CA2081808A1 (en) 1991-11-04 1993-05-05 Maarten De Jonge Combination of calcium antagonists with cholinesterase inhibitors
JPH05140149A (en) 1990-11-22 1993-06-08 Takeda Chem Ind Ltd Condensed heterocyclic derivative
JPH05279355A (en) 1990-10-19 1993-10-26 Ss Pharmaceut Co Ltd Quinoline derivative and medicines containing the same
WO1996012717A1 (en) 1994-10-25 1996-05-02 Toyama Chemical Co., Ltd. Potentiator for nerve growth factor activity containing 1,2-ethanediol derivative or salt thereof
WO1996026196A2 (en) 1995-02-23 1996-08-29 Schering Corporation Benzylpiperidines and piperazines as muscarinic antagonists
WO1997030703A1 (en) 1996-02-20 1997-08-28 Toyama Chemical Co., Ltd. Cerebral function ameliorant containing 1,2-ethanediol derivatives or salts thereof
WO1998001425A1 (en) 1996-07-10 1998-01-15 Schering Corporation 1,4-di-sustituted piperidines as muscarinic antagonists
WO1998005292A2 (en) 1996-08-08 1998-02-12 Schering Corporation Piperidine and piperazine derivatives and their use as muscarinic antagonists
WO1998006697A1 (en) 1996-08-15 1998-02-19 Schering Corporation Ether muscarinic antagonists
JPH10259126A (en) 1997-01-17 1998-09-29 Takeda Chem Ind Ltd Treating and preventing agent for alzheimer's disease
WO1999025363A1 (en) 1997-11-14 1999-05-27 Sanofi-Synthelabo Combination of active principles, in particular of tetrahydropyridins and acetylcholinesterase inhibiting agents, for treating senile dementia such as alzheimer dementia
WO1999031056A1 (en) 1997-12-12 1999-06-24 Toyama Chemical Co., Ltd. Alkyl ether derivatives or salts thereof and calcium antagonists containing the same
WO2000076957A1 (en) 1999-06-11 2000-12-21 Toyama Chemical Co., Ltd. N-alkoxyalkyl-n,n-dialkylamine derivatives or salts thereof, and remedies for nerve degeneration diseases containing the same
WO2003035647A1 (en) 2001-10-19 2003-05-01 Toyama Chemical Co., Ltd. Alkyl ether derivatives or salts thereof
US20050250843A1 (en) 2002-06-14 2005-11-10 Yasushi Nakada Medicinal compositions improving brain function and method for improving brain function
US20060205709A1 (en) 2003-04-17 2006-09-14 Toyama Chemical Co., Ltd. Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof
US20090093453A1 (en) 2006-04-26 2009-04-09 Toyama Chemical Co., Ltd Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof
US20090209512A1 (en) 2006-04-26 2009-08-20 Toyama Chemical Co., Ltd. Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5280032A (en) 1989-02-14 1994-01-18 Toyama Chemical Co., Ltd. 1,2-ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same
JP2925363B2 (en) 1991-07-09 1999-07-28 キヤノン株式会社 Image processing method and apparatus
JP3232830B2 (en) 1993-11-30 2001-11-26 三菱電機株式会社 Carriage mechanism of flexible disk drive
US20030092737A1 (en) 1997-11-14 2003-05-15 Pierre Maffrand Jean Combination of active ingredients for the treatment of senile dementia of the Alzheimer type

Patent Citations (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61225158A (en) 1985-03-05 1986-10-06 プロテ−ラ・アクチエンゲゼルシャフト Phenylcarbamates
US5177082A (en) 1985-11-05 1993-01-05 Yu Chao Mei Huperzines and analogs
JPS62215527A (en) 1986-01-15 1987-09-22 ボニ−、デイビス Alzheimer's sclerosis remedy
JPS6479151A (en) 1987-06-22 1989-03-24 Eisai Co Ltd Cyclic amine derivative
JPH0210827A (en) 1988-06-29 1990-01-16 Matsushita Electron Corp Manufacture of semiconductor device
EP0383281A1 (en) 1989-02-14 1990-08-22 Toyama Chemical Co., Ltd. 1,2-ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same
JPH0347158A (en) 1989-04-26 1991-02-28 Toyama Chem Co Ltd 1,2-ethanediol derivative and salt thereof
US5081117A (en) * 1989-09-28 1992-01-14 Hoechst-Roussel Pharmaceuticals Incorporated 4- and 6-carbamates related to physostigmine and intermediates for the preparation thereof
JPH03232830A (en) 1990-02-05 1991-10-16 Toyama Chem Co Ltd 1,2-ethanediol derivative and its salt
JPH0495070A (en) 1990-08-09 1992-03-27 Toyama Chem Co Ltd 1,2-ethandiol derivative and salt of same derivative
JPH05279355A (en) 1990-10-19 1993-10-26 Ss Pharmaceut Co Ltd Quinoline derivative and medicines containing the same
JPH05140149A (en) 1990-11-22 1993-06-08 Takeda Chem Ind Ltd Condensed heterocyclic derivative
WO1992018493A1 (en) 1991-04-11 1992-10-29 Dr. Willmar Schwabe Gmbh & Co. Benzopyranones, methods of manufacture and use thereof
CA2081808A1 (en) 1991-11-04 1993-05-05 Maarten De Jonge Combination of calcium antagonists with cholinesterase inhibitors
JPH05221877A (en) 1991-11-04 1993-08-31 Troponwerke Gmbh & Co Kg Combination of calcium antagonist and cholineesterase inhibitor
WO1996012717A1 (en) 1994-10-25 1996-05-02 Toyama Chemical Co., Ltd. Potentiator for nerve growth factor activity containing 1,2-ethanediol derivative or salt thereof
WO1996026196A2 (en) 1995-02-23 1996-08-29 Schering Corporation Benzylpiperidines and piperazines as muscarinic antagonists
JPH11501014A (en) 1995-02-23 1999-01-26 シェーリング コーポレイション Benzylpiperidine and piperazine as muscarinic antagonists
WO1997030703A1 (en) 1996-02-20 1997-08-28 Toyama Chemical Co., Ltd. Cerebral function ameliorant containing 1,2-ethanediol derivatives or salts thereof
WO1998001425A1 (en) 1996-07-10 1998-01-15 Schering Corporation 1,4-di-sustituted piperidines as muscarinic antagonists
JPH11514671A (en) 1996-07-10 1999-12-14 シェーリング コーポレイション 1,4-Di-substituted piperidines as muscarinic antagonists
WO1998005292A2 (en) 1996-08-08 1998-02-12 Schering Corporation Piperidine and piperazine derivatives and their use as muscarinic antagonists
JP2000501117A (en) 1996-08-08 2000-02-02 シェーリング コーポレイション Muscarinic antagonist
JP2000500786A (en) 1996-08-15 2000-01-25 シェーリング コーポレイション Ether muscarinic antagonist
WO1998006697A1 (en) 1996-08-15 1998-02-19 Schering Corporation Ether muscarinic antagonists
JPH10259126A (en) 1997-01-17 1998-09-29 Takeda Chem Ind Ltd Treating and preventing agent for alzheimer's disease
JP2001523642A (en) 1997-11-14 2001-11-27 サノフィ−サンテラボ Active ingredients for treating senile dementia such as Alzheimer's dementia, especially the combination of tetrahydropyridines and acetylcholinesterase inhibitors
WO1999025363A1 (en) 1997-11-14 1999-05-27 Sanofi-Synthelabo Combination of active principles, in particular of tetrahydropyridins and acetylcholinesterase inhibiting agents, for treating senile dementia such as alzheimer dementia
WO1999031056A1 (en) 1997-12-12 1999-06-24 Toyama Chemical Co., Ltd. Alkyl ether derivatives or salts thereof and calcium antagonists containing the same
WO2000076957A1 (en) 1999-06-11 2000-12-21 Toyama Chemical Co., Ltd. N-alkoxyalkyl-n,n-dialkylamine derivatives or salts thereof, and remedies for nerve degeneration diseases containing the same
EP1186594A1 (en) 1999-06-11 2002-03-13 Toyama Chemical Co., Ltd. N-alkoxyalkyl-n,n-dialkylamine derivatives or salts thereof, and remedies for nerve degeneration diseases containing the same
US6797726B1 (en) * 1999-06-11 2004-09-28 Toyama Chemical Co., Ltd. N-alkoxyalkyl-N,N-dialkylamine derivatives or salts thereof, and remedies for nerve degeneration diseases containing the same
WO2003035647A1 (en) 2001-10-19 2003-05-01 Toyama Chemical Co., Ltd. Alkyl ether derivatives or salts thereof
US20090111992A1 (en) 2001-10-19 2009-04-30 Toyama Chemical Co., Ltd. Alkyl ether derivatives or salts thereof
US20050250843A1 (en) 2002-06-14 2005-11-10 Yasushi Nakada Medicinal compositions improving brain function and method for improving brain function
US20080103126A1 (en) 2002-06-14 2008-05-01 Toyama Chemical Co., Ltd. Medicinal compositions improving brain function and method for improving brian function
US20060205709A1 (en) 2003-04-17 2006-09-14 Toyama Chemical Co., Ltd. Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof
US20090093453A1 (en) 2006-04-26 2009-04-09 Toyama Chemical Co., Ltd Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof
US20090209512A1 (en) 2006-04-26 2009-08-20 Toyama Chemical Co., Ltd. Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
Ikeda, Ken et al. "T-588, a novel neuroprotective agent, delays progression of neuromuscular dysfunction in wobbler mouse motoneuron disease", Brain Research, vol. 858, No. 1, pp. 84-91 2000.
Mealy et al., Drugs of the future, 2002, 27(9): 879-915. *
Ono, S. et al. "Effects of T-588, a novel cognitive enhancer, on acetylcholine and monoamine releases and second-messenger systems in rats", Society for Neuroscience, vol. 21, p. 947, #377.2 1995.
Ono, S. et al. "T-588, a novel cognition enhancer, protects cortical cell cultures against both beta-amyloid-and 4-hydroxy-2-nonenal-induced apoptosis", Society for Neuroscience, vol. 24, part 1, p. 228, #91.7 1998.
Ono, Satoshi et al. "Protective Effect of R(-)-1-(Benzo[b]thiophen-5-yl)-2-[2-(N,N-diethylamino)ethoxy]ethanol Hydrochloride (T-588), a Novel Celebral Activator, against Experimental Cerebral Anoxia", Japan, J. Pharmacol., vol. 62, No. 1, pp. 81-86 1993.
Ono, Satoshi et al. "Protective Effect of R(−)-1-(Benzo[b]thiophen-5-yl)-2-[2-(N,N-diethylamino)ethoxy]ethanol Hydrochloride (T-588), a Novel Celebral Activator, against Experimental Cerebral Anoxia", Japan, J. Pharmacol., vol. 62, No. 1, pp. 81-86 1993.
Palmer, Gene C. et al. "The Low-Affinity, Use-Dependent NMDA Receptor Antagonist AR-R 15896AR", Annals New York Academy of Sciences, vol. 890, pp. 406-420 1999.
Shimada et al., 1997, CAS:127:362624. *
U.S. Appl. No. 10/553,120, filed Oct. 14, 2005, Kimura, et al.
U.S. Appl. No. 11/416,321, filed May 3, 2006, Saitoh et al.
U.S. Appl. No. 11/957,832, filed Dec. 17, 2007, Nakada, et al.
U.S. Appl. No. 12/253,379, filed Oct. 17, 2008, Saitoh, et al.
U.S. Appl. No. 12/298,656, filed Oct. 27, 2008, Iwakami, et al.
U.S. Appl. No. 12/370,736, filed Feb. 13, 2009, Iwakami, et al.
U.S. Appl. No. 12/542,074, filed Aug. 17, 2009, Kimura, et al.
U.S. Appl. No. 12/683,813, filed Jan. 7, 2010, Nakada, et al.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE43676E1 (en) 2001-10-19 2012-09-18 Toyama Chemical Co., Ltd. Alkyl ether derivatives or salts thereof

Also Published As

Publication number Publication date
AU2003236364C1 (en) 2009-12-24
AU2003236364B2 (en) 2008-08-21
CY1120591T1 (en) 2019-12-11
CY1112958T1 (en) 2016-04-13
NZ537090A (en) 2006-02-24
DK1514542T3 (en) 2012-04-10
NO333504B1 (en) 2013-06-24
WO2003105830A1 (en) 2003-12-24
JP4675103B2 (en) 2011-04-20
EP1514542A4 (en) 2009-06-03
EP2389937A1 (en) 2011-11-30
JPWO2003105830A1 (en) 2005-10-13
IL165589A (en) 2012-04-30
ZA200409901B (en) 2006-07-26
EP1514542A1 (en) 2005-03-16
CN100375619C (en) 2008-03-19
ES2685923T3 (en) 2018-10-15
US7834053B2 (en) 2010-11-16
ATE546140T1 (en) 2012-03-15
EP2389937B1 (en) 2018-08-15
US7342043B2 (en) 2008-03-11
HUE041842T2 (en) 2019-05-28
DK2389937T3 (en) 2018-11-12
CA2488120C (en) 2012-04-17
CA2488120A1 (en) 2003-12-24
BRPI0311780B8 (en) 2021-05-25
NO20045158L (en) 2005-03-10
KR100935615B1 (en) 2010-01-07
KR20050010877A (en) 2005-01-28
EP1514542B1 (en) 2012-02-22
TR201816386T4 (en) 2018-11-21
AU2003236364A1 (en) 2003-12-31
PT2389937T (en) 2018-10-26
CN1662232A (en) 2005-08-31
SI1514542T1 (en) 2012-06-29
US20080103126A1 (en) 2008-05-01
BRPI0311780B1 (en) 2017-09-26
PL372934A1 (en) 2005-08-08
BR0311780A (en) 2005-03-15
MXPA04012534A (en) 2005-04-19
PL217394B1 (en) 2014-07-31
IL165589A0 (en) 2006-01-15
PT1514542E (en) 2012-03-27
US20050250843A1 (en) 2005-11-10
ES2379948T3 (en) 2012-05-07
SI2389937T1 (en) 2018-10-30

Similar Documents

Publication Publication Date Title
US7834053B2 (en) Medicinal compositions improving brain function and method for improving brain function
AU693021B2 (en) Methods of inhibiting cell-cell adhesion
ZA200402806B (en) Alkyl ether derivatives or their salts
KR101233711B1 (en) Alpha-aminoamide derivatives useful as anti-inflammatory agents
CZ285633B6 (en) Use of indole derivatives for preparing medicaments
JP2001527551A (en) Combination of MTP inhibitor and fat-soluble vitamin and method for lowering serum lipid level using the combination
JPH0623105B2 (en) Pharmaceutical composition for the treatment of epileptic seizures
CA1209047A (en) Therapeutic composition containing piracetam analog
EE200100193A (en) Use of 3- (1H-imidazol-4-ylmethyl) -indan-5-ol in the manufacture of a medicament for intraspinal, intra-tea or epidural administration
MY133957A (en) "compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor"
TH18631A (en) How to stop Thrombin
MXPA97005215A (en) Use of 2-phenyl-3-aroylbenzotiophenes to inhibit effects of growth hormone
TH14758B (en) How to stop Thrombin

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1553); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 12